3E Bioventures Capital L.P. 13D/13G Filings for Cytek Biosciences, Inc. (CTKB)

3E Bioventures Capital L.P. 13D and 13G filings for Cytek Biosciences, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-08-03
5:26 pm
Sale		 2022-08-03 13G Cytek Biosciences, Inc.
CTKB		 3E Bioventures Capital L.P. 5,684,615
4.230%		 -4,002,250decrease
(-41.32%)		 Filing
2022-02-16
6:27 pm
Purchase		 2021-12-31 13G Cytek Biosciences, Inc.
CTKB		 3E Bioventures Capital L.P. 9,686,865
7.240%		 9,686,865increase
(New Position)		 Filing